Regulation of gene transcription of B lymphoma Mo‑MLV insertion region 1 homolog (Review)
- Meizhen Zhou
- Qichao Xu
- Deqiang Huang
- Lingyu Luo
Affiliations: Department of Gastroenterology, Research Institute of Digestive Diseases, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China
- Published online on: April 5, 2021 https://doi.org/10.3892/br.2021.1428
Copyright: © Zhou
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
B lymphoma Mo‑MLV insertion region 1 homolog (Bmi‑1) is a core protein component of the polycomb repressive complex 1 that inhibits cell senescence and maintains the self‑renewal ability of stem cells via downregulation of p16Ink4a and p19Arf expression. Bmi‑1 serves an important role in hematopoietic stem cell maintenance and neurodevelopment during embryonic development, and it has been shown to enhance tumorigenesis by promoting cancer stem cell self‑renewal and epithelial to mesenchymal transition. Emerging evidence suggests that Bmi‑1 overexpression is closely related to the development and progression of various types of cancer, and that downregulation of Bmi‑1 expression can inhibit the proliferation, invasion and metastasis of cancer cells. It is therefore important to elucidate the mechanisms underlying the regulation of Bmi‑1 expression both under normal growth conditions and in malignant tissues. In the present review, the current body of knowledge pertaining to the transcriptional and post‑transcriptional regulation of the BMI‑1 gene is discussed, and the potential mechanisms by which Bmi‑1 is dysregulated in various types of cancer are highlighted. Bmi‑1 expression is primarily controlled via transcriptional regulation, and is regulated by the transcription https://www.ushuaia.pl/hyphen/?ln=en factors of the Myc family, including Myb, Twist1, SALL4 and E2F‑1. Post‑transcriptionally, regulation of Bmi‑1 expression is inhibited by several microRNAs and certain small‑molecule drugs. Thus, regulatory transcriptional factors are potential therapeutic targets to reduce Bmi‑1 expression in cancer cells. Thus, the present review provides an up‑to‑date review on the regulation of BMI‑1 gene expression at the transcriptional and post‑transcriptional level.